TiGenix appoints chairman and member of board of directors

21-Sep-2012 - Belgium

TiGenix announced that the Company has appointed JeanStéphenne as independent director and new chairman of the Company's board of directors, and Russell Greig as independent director, in replacement of Koenraad Debackere and Mounia Chaoui-Roulleau, who resigned from the board. Former chairman Willy Duron will remain an independent board member.

Jean Stéphenne was until recently Member of the Corporate Executive Team of GlaxoSmithKline (GSK), and Chairman and President of GSK Biologicals in Wavre, Belgium, which he built into a world leader in vaccines. He currently serves as Chairman of BESIX, IBA and BioWin, and as Director of BNP Paribas Fortis, VBO/FEB, Groupe Bruxelles Lambert (GBL), and Vesalius Biocapital.

Russell Greig worked at GlaxoSmithKline for nearly three decades, most recently as President of SR One, GSK's Corporate Venture Group. Prior to joining SR One, he served as President of GSK's Pharmaceuticals International from 2003 to 2008 and also on the GSK Corporate Executive Team. Dr Greig currently serves as Chairman of AM Pharma in the Netherlands, Isconova AB in Sweden and Syntaxin in the UK, and is a member of the Scottish Science Advisory Council.

The appointments of JeanStéphenne and Russell Greig are effective immediately subject to final appointment by the next shareholders' meeting.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances